Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Neurology(R) Neuroimmunology & Neuroinflammation|April 27, 2022
Pure Relapsing Short Myelitis: Part of the Multiple Sclerosis Spectrum or New Entity?Zélia Poullet, Julie Pique, Adil Maarouf, et al.
Brain Communications|May 21, 2026
Motor tract lesion mapping from the brain to the lower spinal cord in people with relapsing-remitting multiple sclerosis: exploring the association between lesion severity and functional consequences by limbMalo Gaubert, Alice Dufey, Elise Bannier, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|October 5, 2025
Prevalence of hypogammaglobulinemia after non-anti-CD20 therapies and impact of switching to rituximab/ocrelizumab in multiple sclerosisMarine Perriguey, Camille Rigollet, Sean A Freeman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 3, 2024
Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosisMelany Venet, Anne Lepine, Adil Maarouf, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 3, 2016
Improvement of spasticity following intermittent theta burst stimulation in multiple sclerosis is associated with modulation of resting-state functional connectivity of the primary motor corticesClémence Boutière, Caroline Rey, Wafaa Zaaraoui, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 20, 2025
Extended-interval dosing of rituximab/ocrelizumab is associated with a reduced decrease in IgG levels in multiple sclerosisCamille Rigollet, Sean A Freeman, Marine Perriguey, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 16, 2017
Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcomeElisabeth Maillart, Jean-Sebastien Vidal, David Brassat, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 4, 2018
Efficacy of rituximab in refractory RRMSPierre Durozard, Adil Maarouf, Clémence Boutiere, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 9, 2021
TNF-α inhibitors used as steroid-sparing maintenance monotherapy in parenchymal CNS sarcoidosisFrédéric Hilezian, Adil Maarouf, Clemence Boutiere, et al.
JAMA Neurology|February 26, 2014
Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective studyMikael Cohen, Elisabeth Maillart, Ayman Tourbah, et al.
Pageof 6